S&P 500   3,744.59 (-1.02%)
DOW   29,903.11 (-1.22%)
QQQ   280.11 (-0.66%)
AAPL   145.65 (-0.51%)
MSFT   247.29 (-0.77%)
META   139.62 (+0.46%)
GOOGL   101.53 (+0.10%)
AMZN   120.29 (-0.55%)
TSLA   239.26 (-0.64%)
NVDA   131.65 (-0.33%)
NIO   14.86 (-7.36%)
BABA   84.42 (+0.04%)
AMD   68.20 (+0.38%)
T   15.40 (-3.33%)
MU   54.58 (-0.27%)
CGC   2.95 (-3.91%)
F   12.36 (-1.20%)
GE   65.96 (-2.19%)
DIS   100.10 (-0.69%)
AMC   7.21 (-1.64%)
PYPL   94.33 (+0.53%)
PFE   43.14 (-2.22%)
NFLX   240.62 (+1.64%)
S&P 500   3,744.59 (-1.02%)
DOW   29,903.11 (-1.22%)
QQQ   280.11 (-0.66%)
AAPL   145.65 (-0.51%)
MSFT   247.29 (-0.77%)
META   139.62 (+0.46%)
GOOGL   101.53 (+0.10%)
AMZN   120.29 (-0.55%)
TSLA   239.26 (-0.64%)
NVDA   131.65 (-0.33%)
NIO   14.86 (-7.36%)
BABA   84.42 (+0.04%)
AMD   68.20 (+0.38%)
T   15.40 (-3.33%)
MU   54.58 (-0.27%)
CGC   2.95 (-3.91%)
F   12.36 (-1.20%)
GE   65.96 (-2.19%)
DIS   100.10 (-0.69%)
AMC   7.21 (-1.64%)
PYPL   94.33 (+0.53%)
PFE   43.14 (-2.22%)
NFLX   240.62 (+1.64%)
S&P 500   3,744.59 (-1.02%)
DOW   29,903.11 (-1.22%)
QQQ   280.11 (-0.66%)
AAPL   145.65 (-0.51%)
MSFT   247.29 (-0.77%)
META   139.62 (+0.46%)
GOOGL   101.53 (+0.10%)
AMZN   120.29 (-0.55%)
TSLA   239.26 (-0.64%)
NVDA   131.65 (-0.33%)
NIO   14.86 (-7.36%)
BABA   84.42 (+0.04%)
AMD   68.20 (+0.38%)
T   15.40 (-3.33%)
MU   54.58 (-0.27%)
CGC   2.95 (-3.91%)
F   12.36 (-1.20%)
GE   65.96 (-2.19%)
DIS   100.10 (-0.69%)
AMC   7.21 (-1.64%)
PYPL   94.33 (+0.53%)
PFE   43.14 (-2.22%)
NFLX   240.62 (+1.64%)
S&P 500   3,744.59 (-1.02%)
DOW   29,903.11 (-1.22%)
QQQ   280.11 (-0.66%)
AAPL   145.65 (-0.51%)
MSFT   247.29 (-0.77%)
META   139.62 (+0.46%)
GOOGL   101.53 (+0.10%)
AMZN   120.29 (-0.55%)
TSLA   239.26 (-0.64%)
NVDA   131.65 (-0.33%)
NIO   14.86 (-7.36%)
BABA   84.42 (+0.04%)
AMD   68.20 (+0.38%)
T   15.40 (-3.33%)
MU   54.58 (-0.27%)
CGC   2.95 (-3.91%)
F   12.36 (-1.20%)
GE   65.96 (-2.19%)
DIS   100.10 (-0.69%)
AMC   7.21 (-1.64%)
PYPL   94.33 (+0.53%)
PFE   43.14 (-2.22%)
NFLX   240.62 (+1.64%)
NASDAQ:ACHV

Achieve Life Sciences - ACHV Stock Forecast, Price & News

$3.44
-0.14 (-3.91%)
(As of 10/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.39
$3.55
50-Day Range
$3.29
$5.64
52-Week Range
$3.19
$9.06
Volume
15,862 shs
Average Volume
28,602 shs
Market Capitalization
$33.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.33

Achieve Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
641.3% Upside
$25.50 Price Target
Short Interest
Bearish
3.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.88) to ($2.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.53 out of 5 stars

Medical Sector

873rd out of 1,072 stocks

Diagnostic Substances Industry

10th out of 16 stocks

ACHV stock logo

About Achieve Life Sciences (NASDAQ:ACHV) Stock

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Stock News Headlines

ACHV: Autumn Enrollment Completion for ORCA-3
Achieve Life Sciences Misses Q2 EPS by 27c
Achieve Life Sciences Inc - Stock Quote ACHV
Achieve Life Sciences Inc - Stock News
ACHV: First Quarter 2022 Results
Achieve Life Sciences Tops Q1 EPS by 1c
ACHV: Topline Data from ORCA-2 Smoking Cessation Trial
See More Headlines
Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Company Calendar

Last Earnings
8/11/2022
Today
10/06/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACHV
CUSIP
68230A10
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.50
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+636.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-33,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.97 per share

Miscellaneous

Free Float
9,585,000
Market Cap
$33.30 million
Optionable
Not Optionable
Beta
1.27

Key Executives

  • Dr. Richard A. B. Stewart (Age 63)
    Exec. Chairman
    Comp: $660k
  • Mr. John A. Bencich M.B.A. (Age 45)
    CEO & Director
    Comp: $767.25k
  • Dr. Cindy Jacobs M.D. (Age 64)
    Ph.D., Pres, Chief Medical Officer & Director
    Comp: $668.8k
  • Mr. Jerry Wan (Age 40)
    Principal Accounting Officer
  • Dr. Anthony Clarke (Age 66)
    Chief Scientific Officer
  • Ms. Jaime Xinos
    Exec. VP of Commercial













ACHV Stock - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings
or view top-rated stocks.

What is Achieve Life Sciences' stock price forecast for 2022?

1 equities research analysts have issued 12-month target prices for Achieve Life Sciences' stock. Their ACHV share price forecasts range from $24.00 to $27.00. On average, they expect the company's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 641.3% from the stock's current price.
View analysts price targets for ACHV
or view top-rated stocks among Wall Street analysts.

How have ACHV shares performed in 2022?

Achieve Life Sciences' stock was trading at $7.78 at the beginning of the year. Since then, ACHV shares have decreased by 55.8% and is now trading at $3.44.
View the best growth stocks for 2022 here
.

When is Achieve Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ACHV earnings forecast
.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its quarterly earnings results on Thursday, August, 11th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.79) by $0.29. During the same period in the previous year, the company earned ($1.53) EPS.

When did Achieve Life Sciences' stock split?

Achieve Life Sciences shares reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achieve Life Sciences' stock price today?

One share of ACHV stock can currently be purchased for approximately $3.44.

How much money does Achieve Life Sciences make?

Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $33.30 million. The biopharmaceutical company earns $-33,150,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis.

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.

This page (NASDAQ:ACHV) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.